Immunological mechanisms in multiple sclerosis

Clinical and Applied Immunology Reviews

Volumn 5, Issue 4, 2005, Pages 257-269

  Irani, David N ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Autoimmune mechanisms; Experimental autoimmune encephalomyelitis; Immunomodulatory therapy; Multiple sclerosis

Indexed keywords

ATORVASTATIN; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MYELIN PROTEIN; NATALIZUMAB; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; BLOOD SAMPLING; BLOOD TRANSFUSION; BRAIN TISSUE; CELLULAR IMMUNITY; CLINICAL TRIAL; DEMYELINATION; DISEASE COURSE; HUMAN; HUMORAL IMMUNITY; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFECTION; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE FIBER DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN TARGETING; RELAPSE; REMISSION; REVIEW; SPINAL CORD; TRANSLATION REGULATION;

EID: 26944445030     PISSN: 15291049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cair.2005.06.001     Document Type: Review

References (80)

1. J.M. Charcot Histologie de la sclerose en plaques Gaz Hop 41 1868 554-566
2. B.D. Trapp J. Peterson R.M. Ransohoff R. Rudick S. Mork L. Bo Axonal transection in the lesions of multiple sclerosis N Engl J Med 338 1999 278-285
3. J.W. Prineas F. Connell Remyelination in multiple sclerosis Ann Neurol 5 1979 22-31
4. M.A. van Walderveen F. Barkhof P.J. Pouwels R.A. van Schijndel C.H. Polman J.A. Castelijns Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy Ann Neurol 46 1999 79-87
5. T. Kuhlmann G. Lingfeld A. Bitsch J. Schuchardt W. Bruck Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time Brain 125 2002 2202-2212
6. C. Lucchinetti W. Bruck J. Parisi B. Scheithauer M. Rodriguez H. Lassmann Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination Ann Neurol 47 2000 707-717
7. M. Keegan A.A. Pineda R.L. McClelland C.H. Darby M. Rodriguez B.G. Weinshenker Plasma exchange for severe attacks of CNS demyelination: predictors of response Neurology 58 2002 143-146
8. T.M. Rivers F.F. Schwentker Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys J Exp Med 61 1935 689-702
9. P.Y. Paterson Transfer of allergic encephalomyelitis in rats by means of lymph node cells J Exp Med 111 1960 119-133
10. C.B. Pettinelli D.E. McFarlin Adoptive transfer of experimental autoimmune encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: Requirement for Lyt 1+2- T lymphocytes J Immunol 127 1981 1420-1427
11. M.B. Powell D. Mitchell J. Lederman J. Buckmeier S.S. Zamvil M. Graham et al. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein specific T cells correlates with encephalitogenicity Int Immunol 2 1990 539-547
12. J.L. Baron J.A. Madri N.H. Ruddle G. Hashim C.A. Janeway Surface expression of alpha4 integrin by CD4 T cells is required for their entry into brain parenchyma J Exp Med 177 1993 57-68
13. P.V. Lehmann T. Forsthuber A. Miller E.E. Sercarz Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen Nature 358 1992 155-157
14. B.L. McRae C.L. Vanderlugt M.C. Dal Canto S.D. Miller Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis J Exp Med 182 1995 75-85
15. M. Yu J.M. Johnson V.K. Tuohy A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease J Exp Med 183 1996 1777-1788
16. T.A. Yednock C. Cannon L.C. Fritz F. Sanchez-Madrid L. Steinman N. Karin Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin Nature 356 1992 63-66
17. L.B. Nicholson J.M. Greer R.A. Sobel M.B. Lees V.K. Kuchroo An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis Immunity 3 1995 397-405
18. N. Karin D.J. Mitchell S. Brocke N. Ling L. Steinman Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon-γ and tumor necrosis factor-α production J Exp Med 180 1994 2227-2237
19. S. Youssef O. Stuve J.C. Patarroyo P.J. Ruiz J.L. Radosevich E.M. Hur et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 420 2002 78-84
20. M.V. Gardinier P. Amiguet C. Linnington J.M. Matthieu Myelin/ oligodendrocyte glycoprotein is a member of the immunoglobulin superfamily J Neurol Sci 33 1992 177-187
21. C.P. Genain M.H. Nguyen N.L. Letvin R. Pearl R.L. Davis M. Adelman et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate J Clin Invest 96 1996 2966-2974
22. C. Linnington M. Bradl H. Lassmann C. Brunner K. Vass Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein Am J Pathol 130 1988 443-454
23. C.P. Genain B. Cannella S.L. Hauser C.S. Raine Identification of autoantibodies associated with myelin damage in multiple sclerosis Nat Med 5 1999 170-175
24. S.J. Piddlesden H. Lassmann F. Zimprich B.P. Morgan C. Linnington The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement Am J Pathol 143 1993 555-564
25. S.J. Piddlesden M.K. Storch M. Hibbs A.M. Freeman H. Lassmann B.P. Morgan Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis J Immunol 152 1994 5477-5484
26. J. Gausas P.Y. Paterson E.D. Day M.C. Dal Canto Intact B cell activity is essential for complete expression of experimental allergic encephalomyelitis in Lewis rats Cell Immunol 72 1982 360-366
27. M. Allegretta J.A. Nicklas S. Sriram R.J. Albertini T cell responsiveness to myelin basic protein in patients with multiple sclerosis Science 247 1990 718-721
28. J.W. Zhang R. Medaer Y. Chin E. van den Berg-Loonen J.C.M. Raus Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity Ann Neurol 32 1992 330-339
29. A. Lovett-Racke J.L. Trotter J. Lauber P.J. Perrin C.H. June M.K. Racke Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients J Clin Invest 101 1998 725-730
30. C. Scholz K.T. Patton D.E. Anderson G.J. Freeman D.A. Hafler Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation J Immunol 160 1998 1532-1538
31. B. Bielekova B. Goodwin N. Richert I. Cortese T. Kondo G. Afshar et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand Nat Med 6 2000 1167-1174
32. R.S. Fujinami M.B.A. Oldstone Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity Science 230 1985 1043-1045
33. B. Gran B. Hemmer M. Vergelli H.F. McFarland R. Martin Molecular mimicry and multiple sclerosis: Degenerate T cell recognition and the induction of autoimmunity Ann Neurol 45 1999 559-567
34. K.W. Wucherpfennig J.L. Strominger Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein Cell 80 1995 695-705
35. M. Vergelli B. Hemmer M. Kalbus A.B. Vogt N. Ling P. Conlon et al. Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells J Immunol 158 1997 3746-3752
36. H.L.E. Lang H. Jacobsen S. Ikemizu C. Andersson K. Harlos L. Madsen et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis Nat Immunol 3 2002 940-943
37. J.K. Olson J.L. Croxford M.A. Calenoff M.C. Dal Canto S.D. Miller A virus-induced molecular mimicry model of multiple sclerosis J Clin Invest 108 2001 311-318
38. S. Sakaguchi Regulatory T cells: Key controllers of immunologic self-tolerance Cell 101 2000 455-458
39. S. Sakaguchi K. Fukuma K. Kuribayashi T. Masuda Organ-specific autoimmune diseases induced in mice by elimination of a T cell subset. I Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease J Exp Med 161 1985 72-87
40. E. Suri-Payer A.Z. Amar A.M. Thornton E.M. Shevach CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells J Immunol 160 1998 1212-1218
41. S. Read V. Malmstrom F. Powrie Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation J Exp Med 192 2000 295-302
42. B. Salomon D.J. Lenschow L. Rhee N. Ashourian B. Singh A. Sharpe et al. B7/CD28 co-stimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes Immunity 12 2000 431-440
43. A.M. Thornton E.M. Shevach CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production J Exp Med 188 1998 287-296
44. V. Viglietta C. Baecher-Allan H.L. Weiner D.A. Hafler Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis J Exp Med 199 2004 971-979
45. F.W. Gay T.J. Drye G.W. Dick M.M. Esiri The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion Brain 120 1997 1461-1483
46. M.P. Crawford S.X. Yan S.B. Ortega R.S. Mehta R.E. Hewitt D.A. Price et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by a novel flow cytometry assay Blood 103 2004 4222-4231
47. C. Skulina S. Schmidt K. Dornmair H. Babbe A. Roers K. Rajewsky et al. Multiple sclerosis: Brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood Proc Natl Acad Sci U S A 101 2004 2428-2432
48. E.S. Huseby D. Liggitt T. Brabb B. Schnabel C. Ohlen J. Goverman A pathogenic role for myelin-specific CD8+ T cells in a model of multiple sclerosis J Exp Med 194 2001 669-676
49. C. Luchinetti R.N. Mandler D. McGavern W. Bruck G. Gleich R.M. Ransohoff et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica Brain 125 2002 1450-1461
50. V.A. Lennon D.M. Wingerchuk T.J. Kryzer S.J. Pittock C.F. Luchinetti K. Fujihara et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis Lancet 364 2004 2106-2112
51. M. Reindl C. Linnington U. Brehm R. Egg E. Dilitz F. Deisenhammer et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: A comparative study Brain 122 1999 2047-2056
52. T. Berger P. Rubner F. Schautzer R. Egg H. Ulmer I. Mayringer et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event N Engl J Med 349 2003 139-145
53. J.P. Antel A. Bar-Or Do myelin-directed antibodies predict multiple sclerosis? N Engl J Med 349 2003 107-109
54. V. Lampasona D. Franciotta R. Furlan S. Zanaboni R. Fazio E. Bonifacio et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects Neurology 62 2004 2092-2094
55. A.H. Cross J.L. Trotter J.-A. Lyons B cells and antibodies in CNS demyelinating disease J Neuroimmunol 112 2001 1-14
56. B.G. Weinshenker P.C. O'Brien T.M. Petterson J.H. Noseworthy C.F. Lucchinetti D.W. Dodick et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease Ann Neurol 46 1999 878-886
57. H. Lassmann C.S. Raine J. Antel J.W. Prineas Immunopathology of multiple sclerosis: Report on an international meeting held at the Institute of Neurology of the University of Vienna J Neuroimmunol 86 1998 213-217
58. C.F. Brosnan M.B. Bornstein B.R. Bloom The effect of macrophage depletion on the clinical and pathologic expression of EAE J Immunol 126 1981 614-620
59. N.J. Calding D.A.S. Compston Oligodendrocyte macrophage interactions in vitro triggered by specific antibodies Immunology 72 1991 127-132
60. J.W. Prineas J.S. Graham Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown Ann Neurol 10 1981 149-158
61. G. Raivich R. Banati Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating diseases Brain Res Brain Res Rev 46 2004 261-281
62. K.J. Smith H. Lassmann The role of nitric oxide in multiple sclerosis Lancet Neurol 1 2002 232-241
63. A. Bar-Or R.K. Nuttall M. Duddy A. Alter H.J. Kim I. Ifergan et al. Analyses of matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis Brain 126 2003 2738-2749
64. L.T. Diemel C.A. Copelman M.L. Cuzner Macrophage in the CNS: Friend or foe? Neurochem Res 23 1998 341-347
65. W.F. Hickey H. Kimura Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo Science 239 1988 290-293
66. D. van Rossum U.K. Hanisch Microglia Metab Brain Dis 19 2004 393-411
67. P.T. Nelson L.A. Soma E. Lavi Microglia in diseases of the central nervous system Ann Med 34 2002 491-500
68. M.J. Carson Microglia as liaisons between the immune and central nervous systems: Functional implications for multiple sclerosis Glia 40 2002 218-231
69. J.W. Peterson L. Bo S. Mork A. Chang R.M. Ransohoff B.D. Trapp VCAM-1-positive microglia target oligodendrocytes at the border of multiple sclerosis lesions J Neuropathol Exp Neurol 61 2002 539-546
70. V. Brundula N.B. Rewcastle L.M. Metz C.C. Bernard V.W. Yong Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis Brain 125 2002 1297-1308
71. N. Popovic A. Schubart B.D. Goetz S.C. Zhang C. Linnington I.D. Duncan Inhibition of autoimmune encephalomyelitis by a tetracycline Ann Neurol 51 2002 215-223
72. T. Vollmer L. Key V. Durkalski W. Tyor J. Corboy S. Markovic-Plese et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis Lancet 363 2004 1607-1608
73. L.M. Metz Y. Zhang M. Yeung D.G. Patry R.B. Bell C.A. Stoian et al. Minocycline reduces gadolinium-enhancing magnetic resonance lesions in multiple sclerosis Ann Neurol 55 2004 756
74. J.A. Kobashigawa S. Katznelson H. Laks J.A. Johnson L. Yeatman X.M. Wang et al. Effect of pravastatin on outcomes after cardiac transplantation N Engl J Med 333 1995 621-627
75. K. Pahan F.G. Sheikh A.M. Namboodiri I. Singh Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages J Clin Invest 100 1997 2671-2679
76. B. Kwak F. Mulhaupt S. Myit F. Mach Statins as a newly recognized type of immunomodulator Nat Med 6 2000 1399-1402
77. B. Wong W.C. Lumma A.M. Smith J.T. Sisko S.D. Wright T.Q. Cai Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation J Leukoc Biol 69 2001 959-962
78. B.E. Theien C.L. Vanderlugt T.N. Eager C. Nickerson-Nutter R. Nazareno Kuchroo VK et al. Discordant effects of anti-VLA-4 treatment before and after the onset of relapsing experimental autoimmune encephalomyelitis J Clin Invest 107 2001 995-1006
79. D.H. Miller O.A. Khan W.A. Sheremata L.D. Blumhardt G.P.A. Rice M.A. Libonati for the International Natalizumab Multiple Sclerosis Trial Group et al. A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 2003 15-23
80. U.H. von Andrian B. Engelhardt Alpha4 integrins as therapeutic targets in autoimmune disease N Engl J Med 348 2003 68-72